These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 28693903

  • 1. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder.
    Vieta E, Loft H, Florea I.
    Eur Neuropsychopharmacol; 2017 Sep; 27(9):877-884. PubMed ID: 28693903
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL, Harper L, Chrones L, Chan S, Mahableshwarkar AR.
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study.
    Adair M, Bose R, Schmidt SN.
    Curr Med Res Opin; 2024 Sep; 40(9):1637-1645. PubMed ID: 39110846
    [Abstract] [Full Text] [Related]

  • 9. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
    Inoue T, Nishimura A, Sasai K, Kitagawa T.
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
    Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E.
    J Psychopharmacol; 2016 Mar; 30(3):242-52. PubMed ID: 26864543
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Minimal clinically important change in the MADRS anhedonia factor score: A pooled analysis of open-label studies with vortioxetine in patients with major depressive disorder.
    McIntyre RS, Necking O, Schmidt SN, Reines E.
    J Affect Disord; 2024 Oct 15; 363():430-435. PubMed ID: 39032712
    [Abstract] [Full Text] [Related]

  • 15. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
    Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG.
    J Affect Disord; 2016 Dec 15; 206():140-150. PubMed ID: 27474960
    [Abstract] [Full Text] [Related]

  • 16. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT, Sluth LB, Olsen CK.
    J Affect Disord; 2018 Mar 15; 229():421-428. PubMed ID: 29331703
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov 15; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.